Patient no. | Group | Grading* of PALNs | R/T† | SUV1 | SUV2 | RI (%) | Final‡ | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Upper | Lower | ||||||||||||
40 min | 40 min and 3 h | 40 min | 40 min and 3 h | ||||||||||
1 | I | 0 | 0 | 3 | 4 | No | 3.28 | 4.16 | 26.83 | A | |||
2 | I | 0 | 0 | 3 | 4 | No | 3.17 | 3.11 | −1.89 | B | |||
3 | II | 3 | 4 | No | 3.69 | 3.62 | −1.90 | B | |||||
4 | 4 | 5.52 | 6.17 | 11.78 | |||||||||
4 | II | 0 | 0 | 4 | 4 | Pelvis | 6.76 | 7.74 | 14.50 | B | |||
5 | II | 0 | 0 | 4 | 4 | No | 8.70 | 9.38 | 7.82 | A | |||
6 | II | 3 | 4 | Pelvis | 2.65 | 3.06 | 15.47 | A | |||||
3 | 4 | 2.16 | 2.46 | 13.89 | |||||||||
7 | III | 0 | 0 | 4 | 4 | Pelvis | 4.46 | 6.19 | 38.79 | C | |||
8 | II | 0 | 0 | 4 | 4 | L-1/2 | 4.44 | 8.08 | 81.98 | A | |||
9 | I | 0 | 0 | 3 | 4 | No | 3.22 | 6.14 | 90.68 | C | |||
10 | I | 4 | 4 | No | 5.12 | 6.85 | 33.79 | B | |||||
3 | 4 | 2.76 | 3.92 | 42.03 | |||||||||
11 | II | 0 | 0 | 3 | 4 | Pelvis | 3.39 | 3.41 | 0.59 | B | |||
12 | I | 0 | 0 | 4 | 4 | No | 5.74 | 5.84 | 1.74 | B | |||
13 | II | 4 | 4 | Pelvis | 7.20 | 8.98 | 24.72 | A | |||||
4 | 4 | 5.54 | 4.35 | −21.48 | |||||||||
14 | II | 4 | 4 | No | 7.12 | 7.34 | 3.09 | B | |||||
4 | 4 | 7.84 | 7.28 | −7.14 | |||||||||
15 | II | 4 | 4 | L-1/2 | 11.4 | 10.65 | −6.58 | B | |||||
4 | 4 | 4.53 | 4.05 | −10.6 | |||||||||
16 | I | 0 | 0 | 3 | 4 | No | 3.96 | 4.89 | 23.48 | B | |||
17 | I | 4 | 4 | No | 8.43 | 8.82 | 4.63 | B | |||||
4 | 4 | 4.34 | 4.41 | 1.61 | |||||||||
18 | II | 0 | 0 | 4 | 4 | Pelvis | 5.60 | 4.57 | −18.39 | B | |||
19 | I | 0 | 0 | 4 | 4 | No | 10.58 | 9.54 | −9.83 | B | |||
20 | II | 4 | 4 | Pelvis | 6.10 | 6.31 | 3.44 | A | |||||
4 | 4 | 10.30 | 9.16 | −11.07 | |||||||||
21 | II | 4 | 4 | 0 | 0 | L-3/4 | 11.14 | 11.05 | −0.81 | B | |||
22 | I | 0 | 0 | 3 | 4 | No | 3.90 | 5.38 | 37.95 | B | |||
23 | II | 0 | 0 | 3 | 4 | Pelvis | 3.60 | 4.50 | 25.00 | B | |||
24 | I | 4 | 4 | No | 6.82 | 5.66 | −17.01 | B | |||||
4 | 4 | 11.03 | 9.54 | −13.51 | |||||||||
25 | I | 0 | 0 | 4 | 4 | No | 7.07 | 5.49 | −22.35 | C | |||
26 | II | 0 | 0 | 3 | 4 | Pelvis | 3.7 | 4.5 | 21.62 | A | |||
27 | II | 0 | 0 | 4 | 4 | Pelvis | 9.52 | 6.52 | −31.51 | A | |||
28 | I | 4 | 4 | No | 10.3 | 12.08 | 17.28 | B | |||||
4 | 4 | 12.56 | 14.25 | 13.46 | |||||||||
29 | II | 4 | 4 | Pelvis | 4.28 | 3.02 | −29.44 | A | |||||
4 | 4 | 7.1 | 7.6 | 7.04 | |||||||||
30 | III | 0 | 0 | 4 | 4 | L-1/2 | 5.86 | 5.41 | −7.68 | C | |||
31 | I | 3 | 4 | No | 3.59 | 5.41 | 50.70 | B | |||||
4 | 4 | 13.08 | 16.01 | 22.40 | |||||||||
32 | II | 0 | 0 | 2 | 3 | L-1/2 | 2.39 | 2.34 | −2.09 | A | |||
33 | I | 0 | 0 | 2 | 3 | No | 2.49 | 3.37 | 35.34 | C | |||
34 | II | 0 | 0 | 2 | 3 | Pelvis | 2.84 | 3.03 | 6.69 | A | |||
35 | II | 0 | 0 | 2 | 3 | Pelvis | 2.18 | 2.85 | 30.73 | C | |||
36 | I | 0 | 0 | 2 | 3 | No | 1.85 | 1.79 | −3.24 | C | |||
37 | III | 0 | 0 | 2 | 3 | No | 1.88 | 2.03 | 7.98 | C | |||
38 | I | 0 | 0 | 2 | 3 | No | 2.09 | 2.35 | 12.44 | B | |||
Mean ± SD | 5.75 ± 3.11 | 6.09 ± 3.17 | 10.26 ± 24.58 |
↵* Grades are 0 = normal; 1 = insignificant visible lesion; 2 = equivocal, needs further follow-up and evaluation; 3 = probably metastasis; and 4 = significant metastasis.
↵† In R/T (radiation therapy), No = never treated before, Pelvis = radiation field was confined to pelvis, and L-3/4 or L-1/2 = radiation field was applied up to level of L3 or L1.
↵‡ A = pathologically proven, B = concordant positive findings of 18F-FDG PET and CT or MR images, and C = confirmed by second CT or MRI follow-up.